Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Dynavax Technologies Corporation | SCB-2019 (CpG 1018/Alum) | COVID-19 vaccine in adolescents | Phase 2/3 | Data Released | Intramuscular | #ERROR: Failed to execute function |
| Dyne Therapeutics Inc. | DYNE-251 - (DELIVER) | Duchenne muscular dystrophy (DMD) | Phase 3 | Trial Planned | Intravenous | Genetic Disorder |
| Eagle Pharmaceuticals Inc. | RYANODEX (dantrolene sodium) | Nerve agent (NA) exposure | sNDA Filing | Intravenous | N/A | |
| Eagle Pharmaceuticals Inc. | EA-114 | Breast cancer in post-menopausal women | NDA Filing | Oral | Oncology | |
| Eagle Pharmaceuticals Inc. | CAL02 | Severe Community-Acquired Bacterial Pneumonia (SCABP) | Phase 2/3 | Intravenous | Antibiotic | |
| Eagle Pharmaceuticals Inc. | Intravenous amisulpride | Postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age | Phase 2/3 | Ongoing | Intravenous | Anti-Emetic |
| EDAP TMS S.A. | Focal One HIFU - (Endo-HIFU-R1) | Rectal endometriosis | Phase 2 | Data Released | Transrectal | Women's Health |
| EDAP TMS S.A. | Transrectal High-intensity focused ultrasound (TR-HIFU) | Rectal Deep Infiltrating Endometriosis | Phase 3 | Data Released | Transrectal | Women's Health |
